A recent study shows that the investigational drug EP-100--a synthetic cytolytic peptide conjugated to a luteinizing hormone releasing hormone (LHRH) -- may be a treatment option for taxane-resistant ovarian cancer.
For women at risk for an inherited type of breast cancer, the decision to be tested for specific genes and make preventative decisions can be life-changing.
Researchers have discovered that ovarian cancers with ARID1A mutations may be sensitive to treatment with an inhibitor of EZH2 methyltransferase activity.
Adding the PARP inhibitor veliparib to cyclophosphamide did not improve response rates or progression-free survival in ovarian cancer.
Women with bilateral malignant ovarian germ cells tumors may still have a good prognosis and may be able to maintain fertility with conservative treatment.
A new oral tablet formulation of olaparib, a PARP inhibitor (poly (ADP-ribose) polymerase), is safe when combined with chemotherapy in advanced ovarian cancer patients previously treated with other agents.
Clinicians who treat patients with high-grade serous ovarian cancer (HGSOC) may soon have a better way to decide whether the patient could respond to the anti-angiogenesis antibody bevacizumab (Avastin).
CHICAGO--In light of encouraging data from a phase II trial reported at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), the National Cancer Institute (NCI) plans to conduct two phase III clinical tr